FiercePharma3h
AbbVie’s Skyrizi leapfrogs Lilly’s Omvoh to take early lead in IL-23 colitis space: survey
Spherix Global Insights said AbbVie’s Skyrizi has quickly blasted past Eli Lilly’s Omvoh in ulcerative colitis, ...
Eli Lilly’s weight-loss drug no longer in shortage, FDA says
The two-year shortage of Eli Lilly’s blockbuster weight-loss and diabetes drugs is over, the U.S. Food and Drug ...
Eli Lilly plans $4.5 billion facility in LEAP District, bringing investment to $13 billion
The $4.5 billion investment will create the Lilly Medicine Foundry, a center that will combine research and manufacturing ...
Hoodline3d
Texas AG Ken Paxton Sues Eli Lilly and Major PBMs, Alleging Insulin Price Gouging Conspiracy
Texas is suing insulin manufacturers and PBMs, including Eli Lilly and CVS Pharmacy, alleging a scheme to hike insulin prices ...
FiercePharma5d
High-flying Eli Lilly pushes more chips forward with $4.5B 'Medicine Foundry' project
As Eli Lilly has surged to become the most valuable company in biopharma—with a market cap now more than twice that of ...
WFYI4d
Eli Lilly announces additional $4.5 billion investment into central Indiana LEAP District
Eli Lilly announced Wednesday it will invest another $4.5 billion into a new facility at the states controversial LEAP ...
This IPO Biotech Stock Could Be the Next Eli Lilly
Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer.
FierceBiotech8h
AstraZeneca pays CSPC $100M for preclinical heart disease drug, teeing up combos and Lilly rivalry
AstraZeneca has paid CSPC Pharmaceutical Group $100 million for a preclinical cardiovascular disease drug candidate. The deal ...